TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02630732

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain school
Description: 2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back school
Description: Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
Study: NCT03052504

Intervention type: OTHER
Intervention: Registration of complications
Description: Prospective registration

Intervention type: OTHER
Intervention: Registration of complications
Description: Prospective registration
Study: NCT02650336

Intervention type: DRUG
Intervention: contrast
Description: a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract

Intervention type: DRUG
Intervention: contrast
Description: a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
Study: NCT01929239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PSMA Designer T Cells
Study: NCT01759004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: volume, muscle strength, physical condition, BMI
Description: phys. condition, muscle strength, volumetry, BMI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: volume, muscle strength, physical condition, BMI
Description: phys. condition, muscle strength, volumetry, BMI
Study: NCT04353479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab(SHR-1210)
Description: A humanized monoclonal immunoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: A DNA methyltransferase inhibitor
Study: NCT02629796

Intervention type: OTHER
Intervention: CIDP treated (IVIG)
Description: usual treatment with intravenous immunoglobulin
Study: NCT01761825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivabradine
Study: NCT03180164

Intervention type: OTHER
Group type: OTHER
Intervention: hospital anxiety and depression scale
Description: self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
Study: NCT03664154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Feeding (SAFE)
Description: The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls.
Study: NCT03275181

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: Non-invasive assessment of left ventricle structure and function

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: Non-invasive assessment of left ventricle structure and function

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: Non-invasive assessment of left ventricle structure and function

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood pressure
Description: Continuously monitored for 5-30 minutes via finger photoplethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood pressure
Description: Continuously monitored for 5-30 minutes via finger photoplethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood pressure
Description: Continuously monitored for 5-30 minutes via finger photoplethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal Exercise
Description: Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal Exercise
Description: Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal Exercise
Description: Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
Study: NCT05106673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal pathways to care
Description: The first implementation measure focuses on optimal ways of caring for mentally ill patients who are also parents with children living in the household. The main goals of this intervention are the specific information of the referring physician, the indicated referral of mentally ill parents and the consideration of underage children living in the household in the inpatient referral. The two main components are the evaluation of the attitudes of the medical and psychotherapeutic referrers towards the target group and the intervention as well as the development and implementation of an optimal care pathway. The optimization of the allocation is organized by Silke Pawils (University Medical Center Hamburg-Eppendorf).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and training program for the professionals
Description: The second implementation intervention concerns the improvement of the professionals' attitudes, knowledge and skills. The two main components here being the assessment of the current state in all institutions within the clinical centers and the development and implementation of an education and training program. The employees of the randomized clinical centers in the intervention group will get a three-hour training. This intervention is organized by Svenja Taubner (University Hospital Heidelberg, Germany).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic screening
Description: The third implementation intervention includes a systematic screening process to improve detection of mentally ill parents with affected children. Employees of the clinical centers fill out two short questionnaires with the parents. This intervention project is organized by Sibylle M. Winter (Charité, Berlin, Germany).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: No Intervention: Treatment as usual These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
Study: NCT00189618

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 100mg p.o. OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg p.o. OD
Study: NCT00643526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled Auto-injector Containing Placebo
Description: Participants will self-inject placebo subcutaneously at thigh and abdomen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled Auto-injector Containing Placebo
Description: Participants will self-inject placebo subcutaneously at thigh and abdomen.
Study: NCT01244295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment
Description: Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Therapy
Description: Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
Study: NCT03126396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgo 310 3166 dressing
Description: Experimental: Urgo 310 3166 dressing
Study: NCT02395081

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D3 in prenatal vitamin
Description: Women will receive 2000 IU 25(OH)D in prenatal vitamin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4000 IU Vitamin D3 in prenatal vitamin
Description: Women will receive 4000 IU 25(OH)D in prenatal vitamin.
Study: NCT00926861

Intervention type: DEVICE
Intervention: ultrasound
Description: A-scan and B-scan ultrasound at baseline and month 6,12,24

Intervention type: DEVICE
Intervention: OCT
Description: Volume scans of spectralis OCT at baseline and month 6,12,24
Study: NCT04360499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low- weight-high-repetitions training
Description: LWHR refers to a specific form of resistance exercise which utilizes low weights and very high repetitions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates training
Description: Pilates style exercise training
Study: NCT02408107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
Study: NCT04630587

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect restorations
Description: see the Arm description

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect restorations
Description: see the Arm description
Study: NCT02289651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venner
Description: Video-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venner
Description: Video-laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller
Description: Direct-Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller
Description: Direct-Laryngoscopy
Study: NCT03882203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAGE-FluBu
Description: Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
Study: NCT03848754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin 3 mg/m^2
Description: GO 3 mg/m\^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin 3 mg/m^2
Description: GO 3 mg/m\^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin 2 mg/m^2
Description: GO 2 mg/m\^2 on Day 1 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin 2 mg/m^2
Description: GO 2 mg/m\^2 on Day 1 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat - 45 mg
Description: Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat - 45 mg
Description: Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat - 60 mg
Description: Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
Study: NCT01772901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine Intervention
Description: The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
Study: NCT00699803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-PRED
Description: T-PRED sterile ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred Forte
Description: Pred Forte sterile ophthalmic solution
Study: NCT02761395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Al-hijamah
Description: * Strict sterilization of selected anatomical sites.~* Suction using sterile plastic disposable sucking cups~* Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Al-hijamah
Description: * Strict sterilization of selected anatomical sites.~* Suction using sterile plastic disposable sucking cups~* Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 20-40 mg/kg/day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: 20-40 mg/kg/day orally
Study: NCT00763230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
Study: NCT01621542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT2725
Description: WT2725 injection Study drug will be administered every 1-4 weeks
Study: NCT04057534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard therapy for AUD plus Chess-based cognitive treatment
Description: Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting.~Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy for AUD
Description: Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting. Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment
Description: Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smoking cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy for TUD
Description: Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smokind cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week.
Study: NCT03752775

Intervention type: DEVICE
Group type: OTHER
Intervention: Robot assisted upper limb rehabilitation
Description: The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assisted upper limb rehabilitation
Description: The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted upper limb rehabilitation
Description: The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
Study: NCT04352192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of biceps brachii muscle.
Study: NCT02445625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI to train joint attention in ASD
Description: The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
Study: NCT04326699

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral SIJ injection
Description: under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ
Study: NCT03259750

Intervention type: OTHER
Intervention: Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire
Description: Self reported outcome instrument